Mesothelioma
High doses of hyperthermic intrathoracic chemotherapy (HITHOC) help pleural mesothelioma patients. A recent study found that when HITHOC is administered at a high dose, survival rates improve and periods of being disease free increase. HITHOC is the use of chemotherapy during surgery and is an experimental treatment for different types of cancer including mesothelioma. It…
Primary Objective Efficacy of XmAb20717 as defined by objective response (defined as a complete response [CR] or partial response [PR] on two consecutive occasions ≥4 weeks apart) as determined by an independent radiologist according to RECIST v1.1 (modified RECIST for pleural mesothelioma) Secondary Objective Objective response as determined by an independent radiologist according to immune-modified…
Primary Outcome Measures Incidence of Adverse Events (AEs) [ Time Frame: Up to 6 Months ] Time to onset of serious adverse events (SAEs) [ Time Frame: Up to 6 Months ] Time to onset of AEs [ Time Frame: Up to 6 Months ] Time to resolution of AEs [ Time Frame: Up to 6 Months ] Time to resolution of SAEs [ Time Frame: Up to 6 Months ] Incidence of physician seriousness…
A clinical trial called Checkmate 743, which looks at the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), shows that the combination can create a better quality of life when compared with the chemotherapy drugs pemetrexed, cisplatin, and carboplatin. Patient reported outcomes were recently reported. People who took Opdivo and Yervoy had a better survival rate…
Primary Outcome Measures Progression Free Survival assessed locally [ Time Frame: time from first dose of combination Nivolumab-Ipilimumab to first documentation of disease progression or to death from any cause evaluated through the total duration of the study (up to 48 months) ] Progression free survival as assessed by the investigator, defined as the time from first dose of…
Mesothelioma is a hard-to-treat cancer. Usually chemotherapy, surgery, radiotherapy, and immunotherapy are used, but they do not do enough to save people’s lives. Scientists may have figured out why this is the case and could potentially have found the main causes that affect survival. These include stage of the tumor, lymph node status, and histological…
Researchers have found that targeting lung fibrosis can help people with mesothelioma. People with mesothelioma usually suffer from fibrosis, which is the stiffening of tissue surrounding tumors. Certain drugs to treat mesothelioma are not very effective because the fibrosis prevents the drugs from penetrating the tumor. It also prevents the immune system from detecting rogue…
Primary Outcome Measures Dose-limiting Toxicity [ Time Frame: First 21 days of treatment. ] The incidence of DLTs during the DLT assessment period. Frequency and Severity of Adverse Events (AE) [ Time Frame: Screening to 90 days from last dose. ] The incidences and percentages of patients experiencing AEs summarized by NCI CTCAE version 5.0 grade and by causality. Dose Finding [ Time Frame: Screening to…
Researchers are looking at a new treatment for mesothelioma. It is a multimodal treatment (multiple treatments combined) consisting of the immunotherapy drug Keytruda and a new drug called OT-101. OT-101 is an antisense drug, which is a drug that blocks molecules that make certain proteins. The drug is also effective at treating COVID-19. It blocks…
Primary Outcome Measures Phase 1: [ Time Frame: 28 days ] To determine the MTD and dosing schedule of TNG908 Phase 2: [ Time Frame: 16 weeks ] To assess anti-neoplastic activity of TNG908 in patients with MTAP-deleted advanced solid tumors by RECIST v1.1 Secondary outcome Measures Phase 1: [ Time Frame: 16 weeks ] To assess preliminary evidence of anti-neoplastic activity of TNG908 in patients with…
